CA3069934A1 - Negative-positive enrichment for nucleic acid detection - Google Patents

Negative-positive enrichment for nucleic acid detection Download PDF

Info

Publication number: CA3069934A1
Authority: CA; Canada
Prior art keywords: nucleic acid; sample; segment; dna; mutation
Prior art date: 2017-06-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA3069934A

Other languages

English (en)

French (fr)

Inventor

Anthony P. Shuber

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genetics Research LLC

Original Assignee

Genetics Research LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-13

Filing date

2018-06-13

Publication date

2018-12-20

2018-01-23 Priority claimed from US15/877,619 external-priority patent/US10527608B2/en

2018-06-13 Application filed by Genetics Research LLC filed Critical Genetics Research LLC

2018-06-13 Priority to CA3222142A priority Critical patent/CA3222142A1/en

2018-12-20 Publication of CA3069934A1 publication Critical patent/CA3069934A1/en

Status Abandoned legal-status Critical Current

Links

102000039446 nucleic acids Human genes 0.000 title claims abstract description 163
108020004707 nucleic acids Proteins 0.000 title claims abstract description 163
150000007523 nucleic acids Chemical class 0.000 title claims abstract description 163
238000001514 detection method Methods 0.000 title description 25
238000000034 method Methods 0.000 claims abstract description 139
206010028980 Neoplasm Diseases 0.000 claims abstract description 50
239000000523 sample Substances 0.000 claims description 98
230000035772 mutation Effects 0.000 claims description 73
108020005004 Guide RNA Proteins 0.000 claims description 59
108010042407 Endonucleases Proteins 0.000 claims description 54
102000004533 Endonucleases Human genes 0.000 claims description 54
108090000623 proteins and genes Proteins 0.000 claims description 46
102000004169 proteins and genes Human genes 0.000 claims description 42
108060002716 Exonuclease Proteins 0.000 claims description 24
102000013165 exonuclease Human genes 0.000 claims description 24
102000023732 binding proteins Human genes 0.000 claims description 19
108091008324 binding proteins Proteins 0.000 claims description 19
239000002245 particle Substances 0.000 claims description 13
238000012163 sequencing technique Methods 0.000 claims description 13
230000027455 binding Effects 0.000 claims description 11
230000001605 fetal effect Effects 0.000 claims description 11
108700028369 Alleles Proteins 0.000 claims description 10
210000004369 blood Anatomy 0.000 claims description 10
239000008280 blood Substances 0.000 claims description 10
238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 9
230000008774 maternal effect Effects 0.000 claims description 9
238000010186 staining Methods 0.000 claims description 9
238000001493 electron microscopy Methods 0.000 claims description 8
239000007850 fluorescent dye Substances 0.000 claims description 8
238000009396 hybridization Methods 0.000 claims description 8
230000005291 magnetic effect Effects 0.000 claims description 8
238000000399 optical microscopy Methods 0.000 claims description 8
238000002798 spectrophotometry method Methods 0.000 claims description 8
230000003321 amplification Effects 0.000 claims description 5
238000001502 gel electrophoresis Methods 0.000 claims description 5
238000011528 liquid biopsy Methods 0.000 claims description 5
238000003199 nucleic acid amplification method Methods 0.000 claims description 5
238000001179 sorption measurement Methods 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 4
230000007717 exclusion Effects 0.000 claims description 4
238000005342 ion exchange Methods 0.000 claims description 4
239000000696 magnetic material Substances 0.000 claims description 2
239000002907 paramagnetic material Substances 0.000 claims description 2
201000011510 cancer Diseases 0.000 abstract description 17
230000029087 digestion Effects 0.000 abstract description 16
238000000746 purification Methods 0.000 abstract description 4
230000002068 genetic effect Effects 0.000 abstract description 2
108020004414 DNA Proteins 0.000 description 99
239000012634 fragment Substances 0.000 description 35
230000004075 alteration Effects 0.000 description 23
210000002381 plasma Anatomy 0.000 description 20
108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
230000037442 genomic alteration Effects 0.000 description 11
108091033409 CRISPR Proteins 0.000 description 9
208000005443 Circulating Neoplastic Cells Diseases 0.000 description 9
101710163270 Nuclease Proteins 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
239000007795 chemical reaction product Substances 0.000 description 9
210000000349 chromosome Anatomy 0.000 description 8
230000004927 fusion Effects 0.000 description 8
238000010362 genome editing Methods 0.000 description 8
238000013459 approach Methods 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
238000004255 ion exchange chromatography Methods 0.000 description 7
238000002955 isolation Methods 0.000 description 7
230000008685 targeting Effects 0.000 description 7
238000011282 treatment Methods 0.000 description 7
108010017070 Zinc Finger Nucleases Proteins 0.000 description 6
238000010586 diagram Methods 0.000 description 6
230000005945 translocation Effects 0.000 description 6
238000010459 TALEN Methods 0.000 description 5
108091093094 Glycol nucleic acid Proteins 0.000 description 4
108091093037 Peptide nucleic acid Proteins 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
108091046915 Threose nucleic acid Proteins 0.000 description 4
108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000005266 circulating tumour cell Anatomy 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000007481 next generation sequencing Methods 0.000 description 4
-1 rRNA Proteins 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
238000005377 adsorption chromatography Methods 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000000869 mutational effect Effects 0.000 description 3
238000005192 partition Methods 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
108091061744 Cell-free fetal DNA Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
206010062717 Increased upper airway secretion Diseases 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
235000011180 diphosphates Nutrition 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
108091070501 miRNA Proteins 0.000 description 2
239000002679 microRNA Substances 0.000 description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
208000026435 phlegm Diseases 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
230000008569 process Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
210000000582 semen Anatomy 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
238000001542 size-exclusion chromatography Methods 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
238000011529 RT qPCR Methods 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000012620 biological material Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
210000000795 conjunctiva Anatomy 0.000 description 1
238000009223 counseling Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010201 enrichment analysis Methods 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
229920001109 fluorescent polymer Polymers 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
230000004545 gene duplication Effects 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
238000007885 magnetic separation Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
238000001821 nucleic acid purification Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000047 product Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000007671 third-generation sequencing Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)

CA3069934A 2017-06-13 2018-06-13 Negative-positive enrichment for nucleic acid detection Abandoned CA3069934A1 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA3222142A CA3222142A1 (en)	2017-06-13	2018-06-13	Negative-positive enrichment for nucleic acid detection

Applications Claiming Priority (11)

Application Number	Priority Date	Filing Date	Title
US201762519051P	2017-06-13	2017-06-13
US62/519,051		2017-06-13
US201762526091P	2017-06-28	2017-06-28
US62/526,091		2017-06-28
US201762568121P	2017-10-04	2017-10-04
US62/568,121		2017-10-04
US15/877,619 US10527608B2 (en)	2017-06-13	2018-01-23	Methods for rare event detection
US15/877,619		2018-01-23
US201862656592P	2018-04-12	2018-04-12
US62/656,592		2018-04-12
PCT/US2018/037277 WO2018231945A1 (en)	2017-06-13	2018-06-13	Negative-positive enrichment for nucleic acid detection

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA3222142A Division CA3222142A1 (en)	2017-06-13	2018-06-13	Negative-positive enrichment for nucleic acid detection

Publications (1)

Publication Number	Publication Date
CA3069934A1 true CA3069934A1 (en)	2018-12-20

Family

ID=64659281

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA3069934A Abandoned CA3069934A1 (en)	2017-06-13	2018-06-13	Negative-positive enrichment for nucleic acid detection
CA3222142A Pending CA3222142A1 (en)	2017-06-13	2018-06-13	Negative-positive enrichment for nucleic acid detection

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CA3222142A Pending CA3222142A1 (en)	2017-06-13	2018-06-13	Negative-positive enrichment for nucleic acid detection

Country Status (3)

Country	Link
EP (1)	EP3638809A4 (de)
CA (2)	CA3069934A1 (de)
WO (1)	WO2018231945A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10081829B1 (en)	2017-06-13	2018-09-25	Genetics Research, Llc	Detection of targeted sequence regions
EP3625356B1 (de)	2017-08-08	2021-05-19	Depixus	In-vitro-isolierung und anreicherung von nukleinsäuren mittels ortsspezifischer nuklease
US20210040537A1 (en) *	2019-08-08	2021-02-11	Genetics Research, Llc	Selective enrichment
AU2023364547A1 (en)	2022-10-21	2025-04-10	Watchmaker Genomics, Inc.	Methods and compositions for sequencing library normalization

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2817990A1 (en) *	2009-12-23	2011-06-30	Genetic Technologies Limited	Methods of enriching and detecting fetal nucleic acids
WO2015183025A1 (ko) *	2014-05-28	2015-12-03	주식회사 툴젠	표적 특이적 뉴클레아제를 이용한 표적 dna의 민감한 검출 방법
EP3633047B1 (de) *	2014-08-19	2022-12-28	Pacific Biosciences of California, Inc.	Verfahren zur sequenzierung von nukleinsäuren basierend auf einer anreicherung von nukleinsäuren
US10421993B2 (en) *	2015-02-11	2019-09-24	Paragon Genomics, Inc.	Methods and compositions for reducing non-specific amplification products
WO2016134136A2 (en) *	2015-02-20	2016-08-25	The Johns Hopkins University	Genomic alterations in the tumor and circulation of pancreatic cancer patients
US10538758B2 (en) *	2015-08-19	2020-01-21	Arc Bio, Llc	Capture of nucleic acids using a nucleic acid-guided nuclease-based system
US11268144B2 (en) *	2015-09-24	2022-03-08	Sigma-Aldrich Co. Llc	Methods and reagents for molecular proximity detection using RNA-guided nucleic acid binding proteins
EP3625356B1 (de) *	2017-08-08	2021-05-19	Depixus	In-vitro-isolierung und anreicherung von nukleinsäuren mittels ortsspezifischer nuklease
CA3093846A1 (en) *	2018-03-15	2019-09-19	Twinstrand Biosciences, Inc.	Methods and reagents for enrichment of nucleic acid material for sequencing applications and other nucleic acid material interrogations

2018
- 2018-06-13 CA CA3069934A patent/CA3069934A1/en not_active Abandoned
- 2018-06-13 EP EP18817717.4A patent/EP3638809A4/de not_active Withdrawn
- 2018-06-13 CA CA3222142A patent/CA3222142A1/en active Pending
- 2018-06-13 WO PCT/US2018/037277 patent/WO2018231945A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP3638809A4 (de)	2021-03-10
EP3638809A1 (de)	2020-04-22
CA3222142A1 (en)	2018-12-20
WO2018231945A1 (en)	2018-12-20

Legal Events

Date	Code	Title	Description
2024-02-07	FZDE	Discontinued	Effective date: 20231213

Publication	Publication Date	Title
US20200157599A9 (en)	2020-05-21	Negative-positive enrichment for nucleic acid detection
US20200103399A1 (en)	2020-04-02	Methods for rare event detection
US20240327900A1 (en)	2024-10-03	Bodily fluid target enrichment
JP7651497B2 (ja)	2025-03-26	核酸の正確な並行定量のための高感度な方法
US20240209348A1 (en)	2024-06-27	Solid phase negative enrichment
CA3069934A1 (en)	2018-12-20	Negative-positive enrichment for nucleic acid detection
US20180355409A1 (en)	2018-12-13	Tumor mutation burden by quantification of mutations in nucleic acid
US20240052396A1 (en)	2024-02-15	Selective protection of nucleic acids
WO2022034300A1 (en)	2022-02-17	Multiomic analysis of nanoparticle-coronas
Mathot et al.	2013	Automated serial extraction of DNA and RNA from biobanked tissue specimens
CN117625764A (zh)	2024-03-01	准确地平行检测和定量核酸的方法
US20190048425A1 (en)	2019-02-14	Tumor detection and monitoring
US20240309434A1 (en)	2024-09-19	Targeted rare allele crispr enrichment
US20180355437A1 (en)	2018-12-13	Plasma/serum target enrichment
EP4215619A1 (de)	2023-07-26	Verfahren zur sensitiven und genauen parallelen quantifizierung von nukleinsäuren
CA3069939A1 (en)	2019-11-21	Tumor detection and monitoring
CN106282361B (zh)	2021-06-18	用于捕获血液病相关基因的基因捕获试剂盒
US20190071716A1 (en)	2019-03-07	Bodily fluid enrichment
AU2024243779A1 (en)	2025-11-13	Arrays targeting differentially accessible chromatin regions using quantitative polymerase chain reaction
CN111742216A (zh)	2020-10-02	半自动化研究仪器系统
HK40072445A (en)	2022-11-25	Highly sensitive methods for accurate parallel quantification of nucleic acids
US20210079481A1 (en)	2021-03-18	Diagnostic assay for cancer
CN120060475A (zh)	2025-05-30	一种基于ctDNA甲基化和突变共检的肿瘤早筛、诊断探针库、试剂盒及检测方法
HK40126982A (zh)	2026-01-09	准确地平行定量核酸的高灵敏度方法